Navigation Links
Significant Generic Erosion Will Cause Sales of Dyslipidemia Drugs to Decline by $3.6 Billion by 2016
Date:3/19/2008

Statins Will Continue to Dominate Market Despite Patent Expiries and Increased Use of Fixed-Dose Combinations, According to a New Report from

Decision Resources

WALTHAM, Mass., March 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of dyslipidemia therapies will decline from $28 billion in 2006 to $24.4 billion in 2016 owing to significant generic erosion, triggered particularly by the 2006 U.S. patent expiry of Merck's Zocor and the U.S. and European patent expiries of Pfizer's Lipitor beginning in 2010.

The new Pharmacor report entitled Dyslipidemia finds that statins will continue to dominate the dyslipidemia drug market by claiming more than 70 percent patient share in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. However, the sales share of statins will decline from $21 billion in 2006 to $7.8 billion in 2016 owing to generic erosion and greater use of fixed-dose combination therapies that offer dual modes of action and/or modulate high-density lipoprotein (HDL) in addition to low- density lipoprotein (LDL) cholesterol. The fixed-dose combinations class will capture 30 percent of the dyslipidemia market in 2016.

The report also finds that physicians will increasingly prescribe treatment aimed at aggressive LDL targets in high-risk patients, which will benefit more potent agents such as AstraZeneca's Crestor and add-on therapies such as Merck/Schering-Plough's Zetia/Ezetrol. Aggressive treatment will also boost uptake of novel LDL-lowering therapies such as lapaquistat, Takeda's novel squalene synthase inhibitor, which will be used in polypharmacy regimens.

"Although statins are entrenched as the first-line therapy of choice for the vast majority of dyslipidemia patients and have achieved success in lowering both LDL and the risk of heart attacks, the prevalence o
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Carnegie Mellon study shows just listening to cell phones significantly impairs drivers
2. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
3. Novavax CEO to Present at Susquehannas Second SIGnificant Options in Healthcare Conference
4. Abaxis, Inc. to Present at the Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
5. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
6. Advanced Life Sciences to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference
7. Significant Growth for Pinstripe Leads to Need for Larger Facility
8. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
9. AAAS symposium to address significant effects of the male parent in reproductive success
10. Peter G. Peterson Commits $1 Billion Toward Solving Americas Most Significant Economic Challenges
11. Surprising New Research Indicates that Significant Numbers of Children as Young as 11 are Engaging in Sexual Activity and that Dating Violence and Abuse are Part of Their Relationships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Americans report feeling more stressed than ever ... mornings, which puts stressed out people right over the edge. , Almost half ... sleep deprivation every night. Sleeping pills now lead the list of the most prescribed ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... “It is ... founder of SunGrubbies.com. “We are particularly interested in getting the word out to ... years to surface. We are extremely pleased with our new video which ...
(Date:6/29/2015)... ... 30, 2015 , ... Aespala Medspa and Plastic Surgery is proud to introduce ... , Dr. Dreyfuss received his medical degree from Emory University in Atlanta before ... Plastic Surgery Fellowship at the University of Chicago. He has taught and practiced medicine ...
(Date:6/29/2015)... , ... June 30, 2015 , ... ... set of revised Guidelines for Neuro Musculoskeletal Thermography and Sympathetic Skin Response Studies.* ... Guidelines that were first published in 2006, are intended to aid physicians and ...
(Date:6/29/2015)... ... June 29, 2015 , ... Healthpointe, one ... Dr. John A. Mitamura, MD., PhD into their world-class multidisciplinary team of physicians ... Long Beach , Irwindale and La Tijera-Los Angeles. , Orthopedic surgeons ...
Breaking Medicine News(10 mins):Health News:Wake UP Happy and Sleep Soundly with Famous Experts with My Wake UP Call® Motivational Alarm Clock® Messages and My Good Night Messages™ - Now Available at Audible! 2Health News:Wake UP Happy and Sleep Soundly with Famous Experts with My Wake UP Call® Motivational Alarm Clock® Messages and My Good Night Messages™ - Now Available at Audible! 3Health News:SunGrubbies.com, a Leading Online Retailer of Sun Protection Products, Joins Effort to Promote Sun Safety 2Health News:SunGrubbies.com, a Leading Online Retailer of Sun Protection Products, Joins Effort to Promote Sun Safety 3Health News:Aespala Medspa and Plastic Surgery Welcomes New Plastic Surgeon to Oak Brook, IL Office 2Health News:Aespala Medspa and Plastic Surgery Welcomes New Plastic Surgeon to Oak Brook, IL Office 3Health News:American Academy of Thermology Publishes Revised 2015 Guidelines for Neuro-Musculoskeletal Thermography and Sympathetic Skin Response Studies 2Health News:American Academy of Thermology Publishes Revised 2015 Guidelines for Neuro-Musculoskeletal Thermography and Sympathetic Skin Response Studies 3Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 2Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 3
... projects require care and caution , , SUNDAY, March 29 (HealthDay ... yard work -- but if they,re not careful, it might ... with ladders, gardening tools and lawn mowers alone cause hundreds ... according to the U.S. Consumer Product Safety Commission. Many of ...
... produce better outcomes, study finds, , , SUNDAY, March 29 (HealthDay ... hoped would improve symptoms in people with heart failure ... , , The hope was that by isolating the damaged ... heart that pumps blood to the body -- people would ...
... for individuals who want to earn substantial income through sale of products ... Health has created a risk-free, hassle-free affiliate system with tremendous financial upsides. ... affiliate program. , ... New York (PRWEB) March 29, 2009 -- Looking ...
... rose after a defeat, and dropped after a victory , , ... team lose in the Super Bowl could actually end your ... is that a victory might do just the opposite, the ... College of Cardiology annual meeting, in Orlando, Fla. , To ...
... drug warfarin for many patients, researchers say, , , SATURDAY, ... soon replace the anti-clotting drug warfarin as the first ... a new study suggests. , People with atrial fibrillation ... noted, and typically need to take warfarin for the ...
... gestational age, being male did have a correlation , , ... affect the extent of head flattening in infants, U.S. ... severity of asymmetrical head shape, known as deformational plagiocephaly ... condition. , Since the early 1990s, parents have been ...
Cached Medicine News:Health News:Tips to Avoid Spring Cleaning Mishaps 2Health News:New Surgery for Heart Failure Proves Ineffective 2Health News:New Surgery for Heart Failure Proves Ineffective 3Health News:ZEO Health's New Program Offers Answer for Those Looking for Income 2Health News:Super Bowl Loss Can 'Kill' Some Fans 2Health News:New Device Treats Common Heart Rhythm Disorder 2Health News:New Device Treats Common Heart Rhythm Disorder 3Health News:Baby's Sleep Position May Not Affect Severity of Head Flattening 2
(Date:6/29/2015)... , June 29, 2015 BiondVax ... preliminary results from its BVX-006 Phase II clinical trial ... In this trial, M-001 was injected intramuscularly to volunteers ... an administration of the 2014/15 season trivalent influenza vaccine ... safe and well tolerated and induced humoral immune responses, ...
(Date:6/29/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... Russell 1000 Index, effective June 26, 2015. The Russell ... of the U.S. equity universe. It is a subset ... of the largest securities based on a combination of ... "We are pleased to be added to this important ...
(Date:6/29/2015)... SAN JOSE, Calif. , June 29, 2015 ... its expert medical workstation lineup. The high-powered, multi-functional ... th generation Intel® Haswell Core ... processor. Both provide significant data processing and computing ... visual performance, making the unit well suited for ...
Breaking Medicine Technology:BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... , SAN FRANCISCO, Sept. 14 ... reported long-term data with vicriviroc, its investigational CCR5 receptor ... II VICTOR-E1 study in treatment-experienced HIV-infected patients. The ... durable virologic suppression and increased CD4 cell counts, and ...
... September 14 , - ... Ensure Patient Safety and Quality, Safeguard Hospital Reimbursement , ... and leading provider of advanced,solutions for healthcare that utilize ... integrated group of,hospitals and physician practices, will roll out ...
Cached Medicine Technology:Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients 2Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients 3Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients 4Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients 5Novant Health Rolls Out MEDai's Predictive Modeling Solution to Nine Hospitals in Three States 2Novant Health Rolls Out MEDai's Predictive Modeling Solution to Nine Hospitals in Three States 3Novant Health Rolls Out MEDai's Predictive Modeling Solution to Nine Hospitals in Three States 4
... sophisticated Aumated Immunoassay Analyzer that fits in any ... 16 X 16 X 21 inches and weighs ... for physician office laboratories, work stations for small ... well as a dedicated system for specialty testing. ...
... ECi brings true automation and continuous ... Highly sensitive assays for thyroid, anemia, ... metabolism testing are currently available, with ... Vitros ECi can simultaneously process 60 ...
... the Therapeutic Drug Monitoring Market in 1981 ... in use today, this system uses technology ... measure serum drug concentration in a patient. ... different diseases, often exhibit a narrow therapeutic ...
Architect i2000 is a flexible solution for your evolving laboratory providing high throughput and walkaway time with built-in flexibility....
Medicine Products: